Cellectis Stock Surges 6.89% by Midday on December 29, 2025

Continued Momentum from Clinical Trial Data

The current progress follows the catalytic effect generated by the presentation in early December of new encouraging data from the phase 1 clinical trial NATHALI-01 evaluating eti-cel, a dual CAR allogeneic product candidate simultaneously targeting CD20 and CD22, with an overall response rate of 88% and a complete response rate of 63%. This announcement had propelled the stock from 4.02 euros on December 10 to 4.57 euros on December 11. After a technical pullback to 4.14 euros last Friday, the stock has regained 6.89% this Monday, confirming investors' appetite for this biotechnological value. The price is now significantly above its key moving averages, with a 50-day moving average at 3.67 euros and a 200-day moving average at 2.33 euros, showing respective gaps of 20.4% and 89.7% below the current level. This configuration demonstrates a solidly established upward trend over the medium and long term. The presentation of the full phase 1 data is scheduled for 2026, which constitutes a potential catalyst for the coming quarters. The stock is now trading below the major resistance threshold at 4.57 euros, a level corresponding to the recent closing high crossed on December 11.

Arbitration Decision Impact

On December 15, the arbitration tribunal issued its decision in the arbitration between Cellectis and the companies Laboratoires Servier and Institut de Recherches Internationales Servier, pronouncing the partial termination of the licensing contract for the product UCART19 V1, also known as ALLO-501 by Allogene, and requesting that Cellectis begin good faith negotiations with Allogene for the granting of a direct license. This arbitral decision had led to a decline in the stock in the following days, but the impact now seems to be digested by the market. Investors appear to favor the promising clinical prospects of eti-cel and lasme-cel over the contractual uncertainties related to the dispute with Servier. The one-month volatility stands at 28.06%, a high level but characteristic of biotechnological values in clinical development phase where each data announcement can generate significant movements. The beta of 0.20 shows a moderate sensitivity to general market fluctuations, confirming that the stock's valuation depends more on its own scientific advancements than on the macroeconomic context.

Technical Indicators and Market Sentiment

The RSI is at 48, in a strictly neutral zone, suggesting that the bullish movement could continue without excessive tension or overbought situation. This momentum indicator signals that the stock has room for progression before entering a technical overheating zone. The MACD displays a slightly negative histogram at -0.03, with the MACD line at 0.06 very close to its signal line at 0.09, indicating a phase of hesitation in the very short term consistent with a consolidation movement after the recent strong gains. The Bollinger Bands frame the action between 3.44 euros and 4.65 euros, placing the current price in the upper middle part of the technical corridor, which leaves room for an extension of the movement in both directions. The major support threshold is at 3.21 euros, well below the current level, offering a significant safety cushion. The CMF indicator at 0.01 confirms slightly positive monetary flows, while the negative OBV at -144,709 reflects a history of capital outflows contrasting with the recent dynamic. The overall technical configuration remains favorable for a continuation of the upward movement once consolidation is completed, with the stock benefiting from a supportive underlying structure and potential to cross the resistance threshold at 4.57 euros.